Teriparatide BS Mochida
Teriparatide biosimilar developed by Mochida Pharmaceutical. Reference product Forsteo (Forteo in the United States).
Brands by market: Teriparatide BS MOCHIDA (Japan) · Commercial partner or holder: Mochida Pharmaceutical · Company profile
FDANot listed
EMANot listed
MHRANot listed
PMDASep 2019approved
HCNot listed
CDSCONot listed
EDENot listed
Approved or registered in 1 of 7 markets
Connections
About Teriparatide BS Mochida
Teriparatide BS Mochida is the first and only teriparatide biosimilar approved in Japan, in September 2019. Mochida has not named the developer.
Status by market
FDA
United States
Not listed by FDA.
EMA
European Union
Not listed by EMA.
MHRA
United Kingdom
Not listed by MHRA.
PMDA
Japan · Teriparatide BS MOCHIDA
Pharmaceuticals and Medical Devices Agency and MHLWApprovedBrand
Teriparatide BS MOCHIDA
Holder or applicant
Mochida Pharmaceutical
Pathway
Biosimilar (MHLW approval on PMDA review)
Approved
Sep 2019
Indications as licensed
Osteoporosis at high risk of fracture
Presentations
600 microgram subcutaneous kit
Remarks
Teriparatide Biosimilar 1, the first in Japan.
Source
S020 (PMDA) · checked Sep 2026
HC
Canada
Not listed by HC.
CDSCO
India
Not listed by CDSCO.
EDE
United Arab Emirates
Not listed by EDE.
Same developer, other molecules
Other biosimilars in the Atlas developed by Mochida Pharmaceutical: Adalimumab BS MA, Etanercept BS MA, Pegfilgrastim BS Mochida / Nipro, Tocilizumab BS MA.
Chronology
- PMDASep 2019Approved by MHLW
Sources
S020PMDA, list of approved biosimilar products in Japan (as of July 2026) Primary (regulator)
Planning teriparatide biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.